Altshuler Shaham Ltd Sells 7,838,977 Shares of Haleon PLC Sponsored ADR $HLN

Altshuler Shaham Ltd lowered its position in shares of Haleon PLC Sponsored ADR (NYSE:HLN) by 98.7% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 100,000 shares of the company’s stock after selling 7,838,977 shares during the quarter. Altshuler Shaham Ltd’s holdings in Haleon were worth $1,011,000 as of its most recent SEC filing.

A number of other institutional investors have also bought and sold shares of the company. Morgan Stanley boosted its position in Haleon by 16.0% during the fourth quarter. Morgan Stanley now owns 21,495,383 shares of the company’s stock valued at $217,318,000 after acquiring an additional 2,962,856 shares during the last quarter. Norges Bank bought a new stake in Haleon during the fourth quarter valued at $163,529,000. Bank of America Corp DE boosted its position in Haleon by 116.7% during the second quarter. Bank of America Corp DE now owns 12,384,135 shares of the company’s stock valued at $128,423,000 after acquiring an additional 6,669,923 shares during the last quarter. JPMorgan Chase & Co. boosted its position in Haleon by 36.6% during the third quarter. JPMorgan Chase & Co. now owns 11,984,672 shares of the company’s stock valued at $107,503,000 after acquiring an additional 3,207,986 shares during the last quarter. Finally, Sculptor Capital LP boosted its position in Haleon by 5.1% during the fourth quarter. Sculptor Capital LP now owns 10,454,868 shares of the company’s stock valued at $105,699,000 after acquiring an additional 505,000 shares during the last quarter. Institutional investors own 6.67% of the company’s stock.

Haleon Price Performance

HLN stock opened at $8.88 on Thursday. The company has a debt-to-equity ratio of 0.47, a current ratio of 0.92 and a quick ratio of 0.71. Haleon PLC Sponsored ADR has a 1 year low of $8.65 and a 1 year high of $11.28. The stock has a market capitalization of $39.26 billion, a PE ratio of 22.76, a price-to-earnings-growth ratio of 2.07 and a beta of 0.13. The company’s 50-day moving average is $9.29 and its 200-day moving average is $9.89.

Haleon (NYSE:HLN) last posted its earnings results on Saturday, February 14th. The company reported $6.32 earnings per share for the quarter. The business had revenue of $3.65 billion during the quarter. Equities research analysts expect that Haleon PLC Sponsored ADR will post 0.56 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on HLN. Argus raised shares of Haleon to a “strong-buy” rating in a research report on Tuesday, March 17th. Rothschild & Co Redburn cut shares of Haleon from a “strong-buy” rating to a “hold” rating in a research report on Tuesday. Deutsche Bank Aktiengesellschaft reissued a “sell” rating on shares of Haleon in a research report on Thursday, April 30th. Finally, Wall Street Zen raised shares of Haleon from a “hold” rating to a “buy” rating in a research report on Saturday, March 21st. Two equities research analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy”.

Haleon Profile

Haleon plc (NYSE:HLN) is a global consumer healthcare company formed through the separation of a large pharmaceutical group’s consumer health business in 2022. Headquartered in the United Kingdom, Haleon develops, manufactures and markets a broad portfolio of over‑the‑counter medicines, oral health products, vitamins, minerals and supplements, and other consumer health goods designed for daily self‑care and symptom relief.

The company’s product mix spans categories such as oral care (toothpastes and sensitivity treatments), pain relief and analgesics, respiratory remedies, digestive health products, topical treatments and nutritional supplements.